Erratum: Mid-Treatment Positron Emission Tomography–Adaptive Radiotherapy in Stage III Non–Small Cell Lung Cancer: Another Attempt Toward Personalized Care POSITIVE is a prospective trial that ...
BARCELONA, Spain — Breastfeeding is possible even after breast cancer, according to findings from two international studies led by Italian researchers, presented at the European Society for Medical ...
SAN ANTONIO — The randomized phase 3 ZEST trial, which was aimed at evaluating niraparib (Zejula) for prevention or delay of breast cancer recurrence in patients with minimal residual disease (MRD) ...
SurvivorNet on MSN
The evERA Trial: A Promising Treatment Option For Patients With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer
The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...
ARX788 is a next-generation, site-specific antibody-drug conjugate (ADC). Its mechanism of action involves a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), conjugated ...
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study POSITIVE is a prospective trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback